Table of Contents
- Trial overview
- Who participated
- What was measured
- Trial phase and design
- What the trial data are meant to show
Trial overview
The clinical trial data provided for A/CALIFORNIA/7/2009 (H1N1)PDM09-DERIVED STRAIN USED (NYMC X-181) describe a study of influenza immunity in people who received an influenza vaccine.[1] The trial was designed to look at antibody responses to vaccine strains and circulating influenza strains from current and past seasons.[1]
The study title was “Immune responses in health care personnel,” and the condition areas listed were influenza and immunity against influenza.[1] The study was interventional, which means participants received an intervention and researchers observed the effects.[1]
Who participated
The trial focused on health care personnel, a group that may have a higher chance of contact with influenza in daily work.[1] The enrollment was 1,500 people, showing that this was a large study.[1]
This kind of population is important because researchers can study how well the immune system responds in people who may face regular exposure to the flu.[1] The trial data do not list additional eligibility details, so only the reported target group can be described here.[1]
What was measured
The main outcome was humoral immunity, which means the antibody response found in blood samples.[1] Researchers planned to assess antibodies against influenza virus strains included in current and past vaccines, as well as strains that were circulating in the community.[1]
The study used hemagglutination inhibition (HI) testing, and it could also use microneutralization or neutralization tests.[1] These are laboratory tests that help show whether antibodies can block or stop influenza viruses.[1]
The brief summary explains that the trial aimed to assess the presence and amount, or titer, of antibodies against circulating influenza virus strains and vaccine strains of the current season from pre- and post-vaccination serum samples.[1] Serum is the liquid part of blood used for testing antibodies.[1]
Trial phase and design
The study was in Phase 3.[1] Phase 3 trials usually include many participants and help researchers learn more about how an intervention performs in a larger group.[1]
The study type was interventional, and the listed intervention was an influenza vaccine described as inactivated split virus or surface antigen given intramuscularly.[1] The source data do not provide more detail about dosing schedules or comparison groups, so those parts cannot be added here.[1]
What the trial data are meant to show
This trial was built to answer a practical question: after vaccination, do people develop antibodies against influenza strains that matter for current and past seasons?[1] That information helps researchers understand immune response in a real-world group of health care personnel.[1]
Because the endpoint focused on antibody measurements, the study was not mainly about symptoms or illness outcomes in the provided data.[1] Instead, it was about laboratory evidence of immune response after vaccination.[1]
Only one trial record was provided, so the article reflects a single Phase 3 study rather than a large set of different trials.[1]
